| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally |
| α. Enhancing Drug Efficacy by This Combination |
| Achieving Therapeutic Synergy |
Click to Show/Hide |
| Experiment 1 Reporting the Effect of This Combination |
[1] |
| In-vitro Model |
KG-1a |
CVCL_1824
|
Adult acute myeloid leukemia |
Homo sapiens |
| MEG-01 |
CVCL_0425
|
Chronic myelogenous leukemia |
Homo sapiens |
| BV-173 |
CVCL_0181
|
Chronic myelogenous leukemia |
Homo sapiens |
| SUP-B15 |
CVCL_0103
|
B acute lymphoblastic leukemia |
Homo sapiens |
| K-562 |
CVCL_0004
|
Chronic myelogenous leukemia |
Homo sapiens |
| HL-60 |
CVCL_0002
|
Adult acute myeloid leukemia |
Homo sapiens |
| In-vivo Model |
The triple-regulated CRAd carrying SG611-PDCD5 and nude mouse xenograft models of K562 cells were constructed in this study. |
Experimental
Result(s) |
Treatment with SG611-PDCD5 in combination with low-dose daunorubicin elicited more potent anti-proliferative and proapoptotic effects in leukemic cells in a dose-dependent manner. |
